obesity drug news today glp-1 september 29 2025 President Trump announced that Medicare will cover semaglutide (Wegovy) and tirzepatide (Zepbound) for weight management indications for people with obesity. Our senior staff writer Kristen Monaco 🚨 FDA Moves to Permanently

But again, it's 140 degrees Fahrenheit, so it's an infrared sauna, and it's been shown to improve a variety of coronary heart disease, and heart-related conditions, there've been some improvements

The Wegovy pill was approved by the FDA in December 2025 as the first oral GLP-1 for weight loss

The results showed that cinchonine could reduce hepatic steatosis and protect liver injury

Blue Cross Blue Shield plans cover some weight loss medications, yet real-world patients frequently encounter barriers including prior authorization requirements, step therapy protocols, and coverage exclusions

This gives it a dual effect: skin tanning (via MC1R) and libido enhancement (via MC4R)